Azopharma Product Development Group, Inc. has announced the addition of Microdosing and Central Lab services to its clinical pharmacology research facility, AvivoClin Clinical Services, located in Daytona Beach, Florida. This extension of services compliments AvivoClin’s current offerings of Phase I-III studies and is accommodated by the recent facility expansion. Microdosing is an important trend among pharmaceutical and regulatory agencies around the world which provides early pharmacokinetic and pharmcodynamic data in humans. AvivoClin is now able to offer Phase 0 Microdosing solutions to clients which include synthesis and labeling of material, formulation, administration of microdoses in a clinical environment and analysis of samples. Along with Microdosing, AvivoClin will also offer central lab services. By bringing the laboratory testing in house, clients will experience a quicker turn-around time for results, a decrease in errors and a reduction in costs. According to Phil Meeks, Chief Executive Office of Azopharma, “The increased space and capabilities allow us to better serve the growing needs of our clients. Through AvivoClin, Azopharma Product Development Group can support numerous clinical studies simultaneously resulting in higher level of service.
